Literature DB >> 22285107

Impaired decision-making in idiopathic REM sleep behavior disorder.

Taeko Sasai1, Tomoyuki Miyamoto, Masayuki Miyamoto, Masaoki Iwanami, Takashi Abe, Masato Matsuura, Yuichi Inoue.   

Abstract

BACKGROUND: Patients with REM sleep behavior disorder (RBD) frequently develop Parkinson's disease (PD), which can impair decision-making ability. This study was undertaken to investigate decision-making ability and its relation to olfactory function in patients with idiopathic RBD.
METHODS: This study used the Iowa Gambling Task (IGT) and the Sniffin' Stick Test for examination of 38 patients with idiopathic RBD (iRBD) and 34 age-matched healthy control subjects (HC). Associations between these test results and other clinical RBD variables were also assessed.
RESULTS: Total IGT score and Sniffin' Stick Test scores were significantly lower in the iRBD group than in the HC group. The iRBD group IGT scores in the first, third, and final blocks were significantly lower than those of the HC group. In the iRBD group, no association was found between the total IGT score and the Sniffin' Stick Test score or any clinical RBD variable.
CONCLUSIONS: Impaired decision-making associated with iRBD can herald PD. However, decision-making disability is thought to appear irrespective of olfactory dysfunction and progression of RBD pathology.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22285107     DOI: 10.1016/j.sleep.2011.09.012

Source DB:  PubMed          Journal:  Sleep Med        ISSN: 1389-9457            Impact factor:   3.492


  10 in total

1.  What the "man in the moon" can tell us about the future of our brains.

Authors:  Birgit Högl
Journal:  Ann Transl Med       Date:  2017-09

Review 2.  Olfactory Dysfunction as an Early Biomarker in Parkinson's Disease.

Authors:  Michelle E Fullard; James F Morley; John E Duda
Journal:  Neurosci Bull       Date:  2017-08-22       Impact factor: 5.203

Review 3.  Parasomnias: an updated review.

Authors:  Michael J Howell
Journal:  Neurotherapeutics       Date:  2012-10       Impact factor: 7.620

4.  Cognitive performances and mild cognitive impairment in idiopathic rapid eye movement sleep behavior disorder: results of a longitudinal follow-up study.

Authors:  Michele Terzaghi; Chiara Zucchella; Valter Rustioni; Elena Sinforiani; Raffaele Manni
Journal:  Sleep       Date:  2013-10-01       Impact factor: 5.849

Review 5.  REM Sleep Behavior Disorder: Diagnosis, Clinical Implications, and Future Directions.

Authors:  Erik K St Louis; Bradley F Boeve
Journal:  Mayo Clin Proc       Date:  2017-11-01       Impact factor: 7.616

6.  A high-density electroencephalography study reveals abnormal sleep homeostasis in patients with rapid eye movement sleep behavior disorder.

Authors:  Amandine Valomon; Brady A Riedner; Stephanie G Jones; Keith P Nakamura; Giulio Tononi; David T Plante; Ruth M Benca; Melanie Boly
Journal:  Sci Rep       Date:  2021-02-26       Impact factor: 4.379

7.  Apathy and emotion-based decision-making in amnesic mild cognitive impairment and Alzheimer's disease.

Authors:  Sophie Bayard; Jean-Pierre Jacus; Stéphane Raffard; Marie-Christine Gely-Nargeot
Journal:  Behav Neurol       Date:  2014-06-22       Impact factor: 3.342

8.  Meta-Analytic Evidence for a Reversal Learning Effect on the Iowa Gambling Task in Older Adults.

Authors:  Rita Pasion; Ana R Gonçalves; Carina Fernandes; Fernando Ferreira-Santos; Fernando Barbosa; João Marques-Teixeira
Journal:  Front Psychol       Date:  2017-10-11

9.  REM Sleep Behavior Disorder Is Not Associated with a More Rapid Cognitive Decline in Mild Dementia.

Authors:  Luiza Chwiszczuk; Monica Haraldseid Breitve; Kolbjørn Brønnick; Michaela D Gjerstad; Minna Hynninen; Dag Aarsland; Arvid Rongve
Journal:  Front Neurol       Date:  2017-08-07       Impact factor: 4.003

Review 10.  Contribution of the GABAergic System to Non-Motor Manifestations in Premotor and Early Stages of Parkinson's Disease.

Authors:  Ane Murueta-Goyena; Ane Andikoetxea; Juan Carlos Gómez-Esteban; Iñigo Gabilondo
Journal:  Front Pharmacol       Date:  2019-10-30       Impact factor: 5.810

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.